

Wildfire smoke exposure and early childhood respiratory health: a study of prescription claims data

Radhika Dhingra^{1,2*}, Corinna Keeler³, Brooke S. Staley³, Hanna V. Jardel^{3,4}, Cavin Ward-Caviness⁴, Meghan E. Rebuli^{5,6}, Yuzhi Xi¹, Kristen Rappazzo⁴, Michelle Hernandez⁵, Anne Chelminski⁴, Ilona Jaspers^{5,6}, Ana G. Rappold⁴

¹ Department of Environmental Sciences and Engineering, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

² Brody School of Medicine, East Carolina University, Greenville, NC, USA

³ Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

⁴ United States Environmental Protection Agency, Center for Public Health and Environmental Assessment, Research Triangle Park, NC, USA.

⁵ Department of Pediatrics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

⁶ Center for Environmental Medicine, Asthma, and Lung Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

***Corresponding Author:** Radhika Dhingra, PhD, Department of Environmental Science and Engineering, Gillings School of Global Public Health, University of North Carolina, 135 Dauer Drive, C.B 7431, Chapel Hill, NC 27599. E-mail address: RDhingra@unc.edu

Keywords: wildfire, wildfire smoke, smoke exposure, prenatal, perinatal, childhood respiratory disease; prescription claims

28 Abstract

29 Wildfire smoke is associated with short-term respiratory outcomes including asthma exacerbation in
30 children. As investigations into developmental wildfire smoke exposure on children's longer-term
31 respiratory health are sparse, we investigated associations between developmental WSE and first use of
32 respiratory medications. Prescription claims from IBM MarketScan Commercial Claims and Encounters
33 database were linked with wildfire smoke plume data from NASA satellites based on Metropolitan
34 Statistical Area (MSA). A retrospective cohort of live infants (2010-2016) born into MSAs in six western
35 states, having prescription insurance, and whose birthdate was estimable from claims data was
36 constructed (N=184,703); of these, gestational age was estimated for 113,154 infants. MSA, gestational
37 age, and birthdate were used to estimate average weekly smoke exposure days (*smoke-day*) for each
38 developmental period: three trimesters, and two sequential 12-week periods post-birth. Medications
39 treating respiratory tract inflammation were classified using active ingredient and mode of administration
40 into three categories: 'upper respiratory', 'lower respiratory', 'systemic anti-inflammatory'. To evaluate
41 associations between wildfire smoke exposure and medication usage, Cox models associating smoke-days
42 with first observed prescription of each medication category were adjusted for infant sex, birth-season,
43 and birthyear with a random intercept for MSA. Smoke exposure during postnatal periods was associated
44 with earlier first use of upper respiratory medications (1-12 weeks: hazard ratio (HR)=1.094 per 1-day
45 increase in average weekly smoke-day, 95%CI: (1.005,1.191); 13-24 weeks: HR=1.108, 95%CI:
46 (1.016,1.209)); sex-specific HRs varied by post-birth exposure window. Protective associations were
47 observed during gestational windows for both lower respiratory and systemic anti-inflammatory
48 medications; it is possible that these associations may be a consequence of live-birth bias. These findings
49 suggest wildfire smoke exposure during early postnatal developmental periods impact subsequent early
50 life respiratory health.

51 Introduction

52 Over the past two decades, frequency and severity of wildfire events has increased, resulting in
53 greater land area being burned each decade (3.3 and 6.8 million average acres per year in 1990s and
54 2010s, respectively(1)) and substantial economic impact (\$347 billion in 2016) that is expected to grow as
55 wildfire frequency increases (2). Wildfire smoke is a complex chemical mixture of both gases and small
56 particles and a major contributor to particulate matter (PM), including the fine fraction of PM (PM_{2.5})(3)
57 which has been implicated in over 8.8 million premature deaths worldwide (4).

58 Particulate matter (PM) exposure during wildfires is associated with acute respiratory and other
59 outcomes in children (5); in addition, wildfire exposures may increase exacerbation-of-asthma events as
60 indicated by hospitalizations, emergency department visits, and outpatient visits (6). In adults, controlled
61 exposure studies of short-term exposures to woodsmoke have underscored the role of smoke exposure in
62 respiratory dysfunction, and provide evidence of both systemic and respiratory inflammation (7). In
63 studies of biomass – a primary fuel source for wildfires – burning and woodsmoke, exposure to these
64 pollutants was associated with asthma related symptoms including wheeze in children (8). Epidemiologic
65 studies (9–14) provide further evidence that wildfire, woodsmoke, and biomass smoke exposures are
66 associated with an increased risk of respiratory infection and reduced lung function in children (15,16)
67 and adults (17–19).

68 While the acute effects of wildfire or biomass burning exposure have been somewhat established,
69 there is little known about the effects of *in utero* or in early life wildfire particulate matter exposure on
70 longer term respiratory health outcomes. Lung development continues through gestation into the postnatal
71 period, a likely critical window of respiratory susceptibility to air pollution (20). Additionally, PM
72 exposure during gestation (e.g., 21,22) and early childhood (e.g., 23) is linked to sex-specific respiratory
73 health outcomes in humans (21). Additional evidence comes from recent studies of non-human primates
74 where exposure to wildfire smoke in the post-natal period resulted in sex-specific attenuation of host-
75 defense mediators and impaired lung function in adolescence (24).

76 As similar respiratory effects may also be possible in humans, we consider the research question:
77 Does exposure to wildfire smoke during gestation or in the early postnatal period result in earlier first use
78 of anti-inflammatory respiratory medications in early childhood? By investigating the association of
79 smoke exposure during multiple developmental periods with first use of respiratory medication, we
80 identify critical windows of development where exposure to wildfire smoke may result in increased
81 respiratory vulnerability in the population of young children.

82
83

84 **Methods**

85 *Population.*

86 We constructed a retrospective cohort of infants from the IBM MarketScan® Commercial Claims and
87 Encounters Research Database (MarketScan) born into six western U.S. states. MarketScan is a
88 proprietary deidentified claims database, comprised of data from private U.S.-based insurance companies.
89 This private claims dataset includes hospitalizations, outpatient visits, services, and prescription claims
90 data.

91 Children born between January 1, 2010 and December 31, 2016, in metropolitan statistical areas
92 (MSAs) in California, Oregon, Washington, Idaho, Montana, or Nevada (**Figure 1; Table S1**) were
93 eligible. Utilizing a validated algorithm (25,26) and ICD-9 or ICD-10 codes, birthdates were estimated for
94 each live birth (**Appendix 1, Supplementary Material**). The MSA was the smallest geographic unit
95 available in MarketScan, and therefore the primary spatial unit for assessing wildfire smoke exposure.
96 Birthdate and MSA were required to estimate exposure to wildfire smoke for all observations.

97 Each child was required to have continuous enrollment with the insurer with at least 1 week of
98 prescription coverage starting at birth. For each child, follow-up begins after risk period; specifically,
99 follow-up begins at birth for prenatal exposures, and after the post-natal risk period for postnatal
100 exposures. For each outcome, the end of follow-up, measured in weeks, was either date of the outcome,
101 the end date of continuous enrollment, or December 31, 2018, whichever came first. This resulted in two

102 analytic cohorts: the full cohort with 182,387 liveborn children and a sub-cohort with 113,154 liveborn
103 children that also had estimates for gestational age (hereafter, *GA sub-cohort*). This study (IRB No:20-
104 2817) was evaluated and approved by the Institutional Review Board at the University of North Carolina
105 at Chapel Hill.

106

107 *Gestational age estimation.*

108 Gestational age was used in the GA sub-cohort to estimate with greater precision the average
109 weekly number of smoke exposure days for the portion of each trimester completed. For example, if a
110 child had a GA of 34 weeks, T1 and T2 estimates would be calculated as described above, but T3 would
111 be the average weekly smoke exposure from the 27th week to the end of the 34th week.

112 As the MarketScan dataset does not explicitly contain variables for gestational age (GA) at
113 delivery, infant records were linked, where possible, to the birthing parent to allow for GA determination.
114 To estimate GA at birth, we used an algorithm based on ICD-9 codes for the number of completed weeks
115 of gestation, as described in **Appendix 2 (Supplementary Material)** (Adapted from 27); these codes
116 were obtained either from the infants' or the birthing parents' records. Observations with GA were not
117 evenly distributed across time due to the shift from ICD-9 to ICD-10 codes in the fall of 2015. Due to
118 marked changes in GA coding between ICD-9 and ICD-10 codes, we chose to estimate GA based on
119 ICD-9 codes only as they were used for the majority of the study period.

120

121 *Outcome: First use of prescription respiratory medication.*

122 Three outcomes were considered: the first prescription use of (1) upper respiratory, (2) lower
123 respiratory, and (3) systemic anti-inflammatory medication. Classifications for each of the three outcomes
124 are briefly summarized in **Table S2**. As systemic anti-inflammatory medications are often used in acute
125 cases of inflammation or infection that could involve the lower respiratory tract, the upper respiratory
126 tract or other organ system, we chose to analyze them separately from medications used more specifically
127 for the upper or lower respiratory tract. If a child was prescribed medications from two outcome classes

128 on separate or the same claim date, they were assumed to have the event in analysis of both outcomes.

129 Medications were selected using a combination of *mode of administration* (*MSTFMDS* variable in

130 MarketScan), *therapeutic drug classes* (*THERCLS*), and *therapeutic drug groups* (*THERGRP*) as defined

131 in Micromedex RedBook (28) in consultation with a pediatric allergist, and referencing Up-To-Date (29);

132 final classification of medications were validated by two physicians. The outcome event was defined as

133 date of the first fill of prescription respiratory medication in drug claims data.

134

135 *Exposure: Average weekly wildfire exposure smoke-days.*

136 Wildfire smoke exposure data were obtained from the publicly available NASA satellite imagery-

137 based Hazard Mapping System Fire and Smoke product (30,31) and were previously used to generate

138 smoke-day exposure estimates for each ZIP Code Tabulation Area (ZCTA) in the study area (10). These

139 data use visible plumes observed via satellite imaging as an approximation of true wildfire smoke

140 exposure. Using these data, we constructed MSA-level daily smoke-day exposures as follows: First, we

141 used the official crosswalk files released by the United States Office of Housing and Urban Development

142 to define membership within an MSA for each ZCTA in the study area, for each year of the study (32,33).

143 A MSA was defined as having a smoke-day on a given date if at least 25% of the population of the MSA

144 experienced a smoke-day, based on weighting the binary ZCTA smoke-days by year-specific ZCTA

145 population; we refer to this exposure measurement as the “25% threshold” smoke-day.

146 In sensitivity analyses, we further examined how estimated proportion of the MSA population

147 exposed in developing the exposure metric might impact observed associations. Because each MSA

148 contained a differing number of ZCTAs, we also defined two additional exposure measures for use in this

149 sensitivity analyses: (1) if any ZCTA within that MSA had a smoke-day on a given date, the MSA was

150 defined as having a smoke-day on that date [hereafter referred to as “0% threshold”]; and (3) if 50% of

151 the population of the MSA experienced a smoke-day on a given date, based on weighting the binary

152 ZCTA smoke-days by year-specific ZCTA population, the MSA was defined as having a smoke-day on

153 that date [50% threshold]. Thus, the “0% threshold” and “50% threshold” roughly correspond to average

154 weekly smoke-days experienced by greater than 0% or 50% of the MSA's population, respectively
155 (**Figure 2**). All analyses were conducted using each of these exposure thresholds, with the 25% threshold
156 smoke-day exposure utilized in the primary analyses, and the 0% and 50% thresholds applied in
157 sensitivity analyses.

158 Smoke-day exposures were linked to each liveborn child according to residential MSA at birth.
159 For each child, the number of smoke-days were summed in each exposure period and divided by the
160 number of weeks in the period to produce average weekly smoke-day estimates. This transformation
161 allows comparison across periods with differing durations and across individuals with various GAs.
162 Average weekly smoke-day estimates for each period were generated for each of the three exposure
163 thresholds.

164 In the full cohort, we estimated the average weekly wildfire smoke-days for the following time
165 periods: each trimester of gestation, and two consecutive 12-week periods after birth. First, second, and
166 third trimesters (T1, T2, & T3) were assumed to be 280-197, 196-99, & 98-1 days before the estimated
167 date of birth, respectively. In the full cohort, postnatal exposure periods, P1 and P2, were defined 1-84
168 days (1-12 weeks) and 85-168 days (13-24 weeks) after birth, respectively.

169 In the GA sub-cohort, we additionally used GA to more accurately estimate the average weekly
170 smoke-days for the portion of each trimester completed (clarifying example in **Supplementary**
171 **Material**). To distinguish between exposures obtained under the assumption of 40-week gestation (full
172 cohort) and those obtained using estimated GA (GA sub-cohort), we use the suffix '-40w' or '-GA',
173 respectively.

174 175 *Statistical Analyses.*

176 For each trimester and postnatal period, mixed effects Cox proportional hazards models were
177 used to estimate the hazard ratio (HR) for the association between the weekly average smoke-days and
178 each prescription outcome. Follow-up time was counted in weeks. The association between average
179 weekly smoke exposure and first use of medications was estimated using the function below:

180

$$181 \quad \lambda_{ij}(t) = \lambda_o(t) \exp[\beta_1 \text{Smoke}_{ij} + \beta_2 \text{Sex}_{ij} + \beta_3 \text{Birthyear}_{ij} + \beta_4 \text{Birth Season}_{ij} + w_i \text{MSA}_i] \quad (1)$$

182

183 where $\lambda_{ij}(t)$ is the probability of the first filled respiratory prescription at time t for child j in the i^{th} MSA;

184 the MSA into which a child was born is the random intercept, and w_i is vector of coefficients for the

185 random intercept. *Smoke* is the average weekly number of smoke-days for the given trimester or postnatal

186 period. In addition to the two models of postnatal smoke-day exposures, separate models were estimated

187 for the six gestational smoke-day exposure periods (T1-40w, T2-40w, T3-40w, T1-GA, T2-GA, and T3-

188 GA). A proxy for sex-specific hormones during development, *sex* was dichotomous (male/female).

189 *Birthyear* was included to adjust for time trends in both the propensity to prescribe medications and the

190 increasing number of smoke-days. Socioeconomic status was not available in the MarketScan database

191 within which all children were privately insured. The 4-category covariate *Birth Season*, defined as birth

192 during Spring (March-May), Summer (June-August), Fall (September-November), or Winter (December-

193 February), was included to adjust for potential confounding.

194 Results for each trimester exposure are presented both for full cohort (all eligible births, assuming

195 a 40-week gestation) and for the GA sub-cohort (the subset of births with estimable gestational age).

196 Results for each postnatal exposure are presented for the full cohort only. Hazard ratios (HR (95%

197 confidence interval(CI))) are estimated for a one day increase in weekly average smoke-days. Results are

198 presented for all children as well as stratified on sex.

199 Though this analysis focuses on population-level effects rather than specific sub-populations or

200 etiologies (work-in-progress), we recognize that preterm birth (PTB) that may drive our main findings. As

201 such, we also stratified by PTB (defined as <37wks) within the GA-sub-cohort.

202

203

204 RESULTS

205 Across the study region of 60 MSAs in six western states (U.S.A.), each MSA had between 31
206 (Walla Walla, WA) and 24,860 (Los Angeles-Long Beach-Glendale, California) births recorded in
207 MarketScan during 2010-2016, with mean and median of 3,039 and 914 births per MSA, respectively
208 (**Table S1**). Los Angeles, Portland, and Seattle contributed the MSAs with the greatest number of births.
209 Of 182,387 eligible births with estimable birthdates (based on claims codes summarized in **Appendix 1**),
210 89,066 (48.8%) were female, and 113,154 (62.0%) also had an estimable GA (**Table 1**). The number of
211 births per year ranged from 18,578 to 32,721, and the sex distribution remained similar across years. In
212 the full cohort, Cetirizine hydrochloride (54.3%) and Mometasone furoate (34.8%) were the most
213 frequently filled upper respiratory prescriptions; Albuterol sulfate (90.0%) was the most frequently filled
214 lower respiratory prescription; Methylprednisolone, Prednisolone, or Prednisone (86.3%) was the most
215 frequently filled systemic anti-inflammatory prescriptions (**Table S3**).

216 On average, children were exposed to less than one day of smoke per week in each exposure
217 period; the mean trimester exposure ranged from 0.28 to 0.70 weekly smoke-days, and postnatal mean
218 exposure ranged from 0.37 to 0.74, across the thresholds (**Table S4**). Descriptive statistics for the full
219 cohort, the GA sub-cohort and those without GA were relatively comparable (**Table S5**).

220

221 *Postnatal period.*

222 In both the first (P1) and second (P2) postnatal periods, the models reflected an association
223 between smoke-day exposure with earlier first use of upper respiratory medication (P1: HR=1.094 per 1-
224 day increase in weekly smoke-day (1.005, 1.191); P2: HR=1.108 (1.016, 1.209)); **Figure 3, Table 2**). In
225 the P1 period, female children had the larger effect size and stronger association (HR=1.123 (0.994,
226 1.27)) as compared to males (HR=1.055 (0.940, 1.185)). In contrast, male children had a larger effect size
227 (HR=1.128 (1.004, 1.266)) and stronger association in P2, as compared to female children (HR=1.072
228 (0.942, 1.22); **Figure 3, Table 2**). Associations in primary models (i.e., using the 25% threshold) of lower
229 respiratory as well as systemic anti-inflammatory outcomes were largely null (**Figure 3, Table 2**).

230

231 *Gestational period*

232 Positive associations with smoke exposure were observed only in the first trimester for the upper
233 respiratory outcome. The 40w- and GA- exposure models produced HRs in the same direction with
234 comparable magnitude, and with some variation in precision (**Figure 3, Table 3**).

235 *Upper respiratory.* In the primary model, the impact of smoke-days on the upper respiratory
236 medications outcome varied by gestational period, with increased risk in the first trimester, and null or
237 decreased risk in the second and third trimester (**Figure 3, Table 3**). In the first trimester, smoke-day
238 exposure was associated with shorter times to first upper respiratory medication, among all (HR=1.082
239 (0.985, 1.188)), and female children (HR=1.140 (0.997, 1.303)) among the full cohort (T1-40w), but not
240 in male children (HR=1.026 (0.902, 1.167); **Figure 3**); these first trimester HRs are comparable in the GA
241 sub-cohort (T1-GA), albeit with less precision in the 95%CI. For all other exposure windows, generally
242 null associations were consistently observed in both the full cohort and the GA sub-cohort.

243 *Lower respiratory.* Smoke-days had a null or slightly inverse association across all three
244 trimesters in the 40-week exposure modeled in both the full cohort and the GA sub-cohort (**Figure 3,**
245 **Table 3**). In contrast to first trimester upper respiratory outcome findings, first trimester smoke-day
246 exposure among the full cohort (T1-40w) was associated with delayed first lower respiratory medications
247 among all (HR=0.977 (0.951, 1.003)) and male children (HR=0.960 (0.927, 0.993)), but not in female
248 children (HR=0.997 (0.956, 1.039); **Figure 3**).

249 *Systemic Anti-inflammatory.* Second trimester smoke-day exposures in the GA sub-cohort (T2-
250 GA) were inversely associated with longer time to the use of systemic anti-inflammatory medication in all
251 (HR=0.946 (0.905, 0.989)) and male (HR=0.921 (0.869, 0.987)) children (**Figure 3, Table 3**). Similar,
252 but smaller magnitude associations were observed in the first trimester (T1-GA) (All: HR=0.962 (0.927,
253 0.997); male: HR=0.959 (0.914, 1.006); **Figure 3**). Interestingly, a similar protective association was
254 found among female children in the third trimester (T3-GA) (HR=0.935 (0.892, 0.992)), but not among

255 male children. In the full cohort, the exposures across all trimesters and groups produce consistent and
256 similarly precise associations that are closer to the null than their counterparts in the GA sub-cohort.

257

258 *Sensitivity analyses*

259 In the postnatal period, HRs and 95% CIs for both upper respiratory and systemic anti-
260 inflammatory outcomes are approximately similar across the 0%, 25% and 50% exposure thresholds
261 (**Figure S1**). For the lower respiratory outcome, however, results in the exposure sensitivity analyses are
262 more variable across thresholds.

263 For all trimester outcomes, the various thresholds used to generate smoke-day exposure estimates
264 generally had little effect on HR estimates, with some marginal changes in the confidence interval
265 precision (**Figure S1**). HR did not markedly differ between term births and PTBs.

266

267

268 DISCUSSION

269 Using private insurance claims data, we conducted a time-to-event analysis to estimate the
270 association between developmental exposure to wildfire smoke and first use of respiratory medication.
271 We found an association between smoke exposure during the first trimester, and both postnatal periods
272 with shorter time to first use of upper respiratory medication; these results were robust across exposure
273 definitions. This positive association between wildfire exposure and upper respiratory medication used
274 was larger for female children in the first trimester and the first 12-week postnatal period, while it was
275 stronger for male children in the 13-24 postnatal week period. These stratified results may suggest sex-
276 specific windows of vulnerability.

277 Additionally, for both systemic anti-inflammatory medication and lower respiratory medication,
278 protective effects of wildfire exposure were observed during most gestational windows. Most
279 prominently, we observed a shorter time to first lower respiratory medication use among male children
280 and all children during the first trimester; this finding was relatively consistent across cohort specification

281 (i.e., full cohort vs GA sub-cohort). Similarly, all children and male children had shorter times to first
282 systemic anti-inflammatory medication with increased smoke exposure during the first and second
283 trimesters; this was true also of girls in the first trimester. Whether the mechanism for these observed
284 protective effects is an artifact of observational epidemiology or a causal biological finding cannot be
285 ascertained in this dataset.

286 Our findings suggest a complex epidemiological relationship between gestational exposure to
287 wildfire smoke and time to first symptoms requiring respiratory prescription use. The juxtaposition of
288 below-null HRs during gestation with evidence in the literature suggesting that ambient air pollution is
289 not protective indicates that this analysis may suffer from selection bias (as do most perinatal
290 epidemiological studies (34)). In administrative datasets, these analyses are necessarily limited to live
291 births, and do not capture pregnancy loss. If the *in utero* response to wildfire smoke exposure is strong,
292 restricting the cohort to live births could lead to attrition of susceptible pregnancies and to an *in utero*-
293 outcome association which is biased to appear less harmful or even protective. Indeed, non-human
294 primate work shows pregnancy loss is associated with wildfire smoke exposure (35).

295 The differing exposure pathways in the gestational and postnatal periods could also account for
296 the discrepancy in findings between these two developmental windows. Broadly, possible pathways for
297 air pollutants to exert influence on a fetus include altered placentation or placenta-mediated processes,
298 and direct fetal exposure. Recent work showed that PM can deposit in placental tissue and, to a lesser
299 extent, pass through the placenta to fetal capillaries (36–38). The increased tidal volume in the birthing
300 parent as well as the increased respiratory rate in young children may result in a larger dose of air
301 pollutants (39,40). Should this increased deposition of wildfire smoke pollutants in the birthing parent
302 impair placentation, there may be increased fetal loss as observed in non-human primates and mentioned
303 above (35). In the surviving fetuses, however, our inconsistent or null findings in the gestational period as
304 compared to positive upper respiratory postnatal findings, could indicate that direct exposure to nasal
305 epithelia, as occurs in the postnatal period, produces a more prominent and detectable increase in use of
306 respiratory medications.

307 Previous studies of PM exposures suggest specific respiratory conditions that could result from
308 wildfire smoke exposure, and may or may not require prescriptions treatment. For example,
309 developmental exposures to PM or biomass burning are associated with early life deficits in lung function
310 (41–43), and increased susceptibility to acute respiratory infection (ARI) or infant bronchiolitis (44,45).
311 While ARI is often treated with prescription medication in young children, subclinical deficits in lung
312 function associated with developmental air pollution exposure may not always be identified and treated
313 with prescription medication unless they lead to respiratory infection (21,43,46–51). It is possible that
314 study cohort members experienced respiratory symptoms that were transient, sub-clinical or well-
315 managed with non-prescription medication, and thus were not captured in this analysis blunting any
316 potential association.

317 Because lung development occurs in phases starting in early gestation and continuing into
318 adolescence, damage in early life may have lasting negative effects. As PM is a component of wildfire
319 smoke exposure, the mechanisms by which such negative effects occur likely include a combination of
320 oxidative stress and inflammation, which may further induce physiological (52–54) or epigenetic changes
321 in the birthing parent and/or offspring (55,56). Early gestational exposure may lead to abnormal cellular
322 differentiation or branching due to a disruption of essential redox signaling (52), while later exposure may
323 induce structural or functional abnormalities (53,54). In non-human primates, early life exposure to
324 woodsmoke has been linked to reduced lung function metrics (24) which may be due to epigenetic
325 changes to respiratory tissues (57).

326 To our knowledge, this is the first analysis describing the impact of exposure to wildfire smoke
327 during development on prescription-treated respiratory conditions in human children. There are several
328 additional strengths in this analysis. We were able to represent multiple exposure scenarios by using
329 various thresholds for assigning smoke-days to an MSA. For example, because the definition of smoke-
330 day is based on the appearance of a plume from satellite data, adjacent areas may indeed be exposed to a
331 lower level of smoke that, while not visible, is still impactful; this scenario is captured by the 0%
332 threshold. We also explored refining exposure estimate using GA. Despite losing 38% of the dataset by

333 including claims-based estimates of GA, exaggerated effect estimates observed in the GA sub-cohort
334 suggest that accounting for GA captures important aspects of exposure relative to fetal development that
335 the assumption of 40-week gestation does not. The use of prescription claims data more accurately
336 captures medication usage than diagnosis or prescription delivery captured in electronic medical records.
337 Further the thorough categorization of these medications by two physicians ensures that they are
338 meaningfully classified. Finally, we were the first to leverage two widely used datasets to answer our
339 research question: well-vetted wildfire exposure data and private claims data able to capture prescription
340 usage.

341 First use of respiratory prescription medication as described in a private insurance claims
342 database serves as an indicator of respiratory health and vulnerability; this approach is not without
343 limitations. The MarketScan Commercial Claims and Encounters database is limited by omission of those
344 who are not on private insurance and those living in rural areas; this could make our results less
345 generalizable to other groups because of socioeconomic factors. While the MarketScan claims database
346 allows the examination of a large population distributed over a large wildfire-impacted region, the
347 availability of individual-level confounders, such as race, SES, and maternal or second-hand smoking, is
348 unfortunately limited. As observed with other air pollutant exposures (58), SES could modify the effect of
349 smoke exposure on respiratory health. Relatedly, this analysis assumes that all participants are exposed to
350 the same proportion of outdoor air pollution (e.g., that they spend the same amount of time outside and all
351 have the same/no indoor air purification systems), which may contribute to the potential for exposure bias
352 differential on SES or other related factors.

353 Imprecision in the estimates of residence may lead to exposure misclassification, though this
354 impact is expected to be small given the size of a MSA in which exposures are defined as uniform due to
355 the spatial coarseness of the data. MSA at birth provides a relatively coarse estimate of exposure which
356 could be improved upon by using a dataset which includes more granular residential information. We also
357 assumed that the MSA at time of birth was the same during the entirety of gestation; while likely not
358 universally true, the impact of this assumption is expected to be small with potential bias toward the null

359 (59,60). Additionally, the coarseness of gestational age available in the ICD-9 coding system, wherein
360 codes are available at 2-week intervals between 24-37 weeks (inclusive), somewhat limits the accuracy of
361 our exposure estimates in the GA sub-cohort; such exposure misclassification may also induce bias in the
362 effect estimates. Finally, some respiratory outcomes may be lost by claims data, as it is only able to
363 provide information on conditions treated by prescription for those who have access to necessary care.

364 The modest differences in associations by sex found in this analysis contribute to growing
365 evidence supporting sex-differential effects of wildfire smoke exposure. There are well-documented sex
366 differences in lung development and asthma (61), including stress-induced oxidative response among
367 fetuses (62). Noted sex-specific reductions in lung function in non-human primates following wildfire
368 smoke exposure during infancy (24) may be exacerbated by prenatal PM exposure (21).

369 Overall, these findings suggest that first trimester and postnatal wildfire smoke exposure is
370 associated with shorter time to the first upper respiratory medication usage, while gestational wildfire
371 smoke exposure across trimesters is associated with longer time to systemic anti-inflammatory respiratory
372 prescription usage. This research supports the growing body of literature indicating that wildfire smoke
373 exposure in early life poses a health risk for pediatric populations, and adds granularity to the current
374 understanding of sex-specific and trimester-specific effects of in utero wildfire smoke exposure.
375 Clinicians may consider discussing the potential benefits of reducing exposure using evidenced-based
376 measures such as observing air quality index alerts, placing air purifiers in their home, and wearing face
377 masks to reduce particulate exposures. Future work should investigate specific clinical outcomes, such as
378 acute respiratory infection, and utilize finer spatial and temporal granularity to refine estimates of wildfire
379 smoke exposure. This work also highlights the continued need to evaluate measures to protect against
380 wildfire smoke during key developmental stages.

381

382 **Declarations:**

383 **Authors contributions:** RD, MER, and IJ conceived of the study question. AGR, CWC, and IJ obtained
384 study funding. RD, CK, YX, and BSS built the dataset and carried out statistical analyses. KR, AGR, and

385 CW-C advised on statistical analyses and cohort development from claims data. RD classified
386 medications as to the outcome and AC and MH reviewed these classifications. RD, CK, and HVJ drafted
387 the manuscript.

388 **Consent for publication** All authors revised the manuscript critically for intellectual content, gave final
389 approval of the version to be published, and agreed to be accountable for all aspects of the work.

390 **Competing interests:** The authors declare they have no competing interests to disclose.

391 **Funding:** Supported by the Environmental Protection Agency (EPA) Cooperative Agreement (U.S. EPA
392 CR83578501); HVJ was supported in part by an appointment to the ORISE participant research program
393 supported by an interagency agreement between EPA and DOE. CK was supported in part by a training
394 grant from the National Institute of Environmental Health Sciences [T32ES007018]. BSS was supported
395 by the Genetic Epidemiology of Heart, Lung, and Blood Traits Training Grant [T32HL129982].

396 **Disclaimer:** The views expressed in this article are those of the authors and do not necessarily represent
397 the views or policies of the U.S. Environmental Protection Agency.

398 **Availability of data and materials:** IBM MarketScan® Research Databases, a proprietary claims
399 dataset, on which these analyses are based are available through IBM

400 (<https://www.ibm.com/products/marketscan-research-databases>). The environmental data from the
401 NOAA Hazards Mapping System that support the conclusions of this article are available in the U.S. EPA
402 Environmental Dataset Gateway (<https://www.ospo.noaa.gov/Products/land/hms.html> - maps).

403 **Ethics approval:** This study (IRB No:20-2817) was evaluated and approved by the Institutional Review
404 Board at the University of North Carolina at Chapel Hill.

405 **Acknowledgements:** The authors would like to acknowledge Michele Jonnson-Funk, Virginia Pate, and
406 Tom Luben for their support and guidance in this developing this work.

407

408 **Abbreviations:**

409 WSE: Wildfire smoke exposure

- 410 MSA: Metropolitan Statistical Area
- 411 PM: Particulate matter
- 412 PM_{2.5}: fine fraction of particulate matter
- 413 MarketScan: IBM MarketScan® Commercial Claims and Encounters Research Database
- 414 ICD: International Classification of Disease
- 415 ZCTA: ZIP Code Tabulation Area
- 416 MSTFMDS: mode of administration
- 417 THERCLS : therapeutic drug classes
- 418 THERGRP : therapeutic drug groups
- 419
- 420 GA: Gestational Age
- 421 T1, T2, T3: 1st, 2nd and 3rd trimesters, respectively
- 422 P1 and P2: 1st and 2nd consecutive 12-week postnatal period, respectively
- 423 HR: hazard ratio
- 424 95% CI: 95% confidence interval
- 425 PTB: pre-term birth

426 References:

- 427 1. National Interagency Fire Center. Total Wildland Fires and Acres (1983-2021) [Internet].
428 [cited 2022 Mar 24]. (Statistics). Available from: [https://www.nifc.gov/fire-](https://www.nifc.gov/fire-information/statistics/wildfires)
429 [information/statistics/wildfires](https://www.nifc.gov/fire-information/statistics/wildfires)
- 430 2. Fann N, Alman B, Broome RA, Morgan GG, Johnston FH, Pouliot G, et al. The health
431 impacts and economic value of wildland fire episodes in the U.S.: 2008–2012. *Sci Total*
432 *Environ*. 2018 Jan 1;610–611:802–9.
- 433 3. Liu JC, Peng RD. The impact of wildfire smoke on compositions of fine particulate matter
434 by ecoregion in the Western US. *J Expo Sci Environ Epidemiol*. 2019 Nov;29(6):765–76.
- 435 4. Lelieveld J, Pozzer A, Pöschl U, Fnais M, Haines A, Münzel T. Loss of life expectancy from
436 air pollution compared to other risk factors: a worldwide perspective. *Cardiovasc Res*. 2020
437 Sep 1;116(11):1910–7.
- 438 5. Künzli N, Avol E, Wu J, Gauderman WJ, Rappaport E, Millstein J, et al. Health effects of
439 the 2003 Southern California wildfires on children. *Am J Respir Crit Care Med*. 2006 Dec
440 1;174(11):1221–8.
- 441 6. Reid CE, Maestas MM. Wildfire smoke exposure under climate change: impact on
442 respiratory health of affected communities. *Curr Opin Pulm Med*. 2019 Mar;25(2):179–87.
- 443 7. Rebuli ME, Speen AM, Martin EM, Addo KA, Pawlak EA, Glista-Baker E, et al. Wood
444 Smoke Exposure Alters Human Inflammatory Responses to Viral Infection in a Sex-Specific
445 Manner. A Randomized, Placebo-controlled Study. *Am J Respir Crit Care Med*. 2019 Apr
446 15;199(8):996–1007.
- 447 8. Sigsgaard T, Forsberg B, Annesi-Maesano I, Blomberg A, Bølling A, Boman C, et al. Health
448 impacts of anthropogenic biomass burning in the developed world. *Eur Respir J*. 2015
449 Dec;46(6):1577–88.
- 450 9. DeFlorio-Barker S, Crooks J, Reyes J, Rappold AG. Cardiopulmonary Effects of Fine
451 Particulate Matter Exposure among Older Adults, during Wildfire and Non-Wildfire Periods,
452 in the United States 2008-2010. *Environ Health Perspect*. 2019 Mar;127(3):37006.
- 453 10. Wettstein ZS, Hoshiko S, Fahimi J, Harrison RJ, Cascio WE, Rappold AG. Cardiovascular
454 and Cerebrovascular Emergency Department Visits Associated With Wildfire Smoke
455 Exposure in California in 2015. *J Am Heart Assoc*. 2018;7(8):e007492.
- 456 11. Rappold AG, Stone SL, Cascio WE, Neas LM, Kilaru VJ, Carraway MS, et al. Peat bog
457 wildfire smoke exposure in rural North Carolina is associated with cardiopulmonary
458 emergency department visits assessed through syndromic surveillance. *Environ Health*
459 *Perspect*. 2011 Oct;119(10):1415–20.
- 460 12. Haikerwal A, Akram M, Del Monaco A, Smith K, Sim MR, Meyer M, et al. Impact of Fine
461 Particulate Matter (PM_{2.5}) Exposure During Wildfires on Cardiovascular Health Outcomes.
462 *J Am Heart Assoc*. 2015 Jul 15;4(7):e001653.

- 463 13. Morgan G, Sheppard V, Khalaj B, Ayyar A, Lincoln D, Jalaludin B, et al. Effects of
464 bushfire smoke on daily mortality and hospital admissions in Sydney, Australia. *Epidemiol
465 Camb Mass*. 2010 Jan;21(1):47–55.
- 466 14. Delfino RJ, Brummel S, Wu J, Stern H, Ostro B, Lipsett M, et al. The relationship of
467 respiratory and cardiovascular hospital admissions to the southern California wildfires of
468 2003. *Occup Environ Med*. 2009 Mar;66(3):189–97.
- 469 15. Mishra V. Indoor air pollution from biomass combustion and acute respiratory illness in
470 preschool age children in Zimbabwe. *Int J Epidemiol*. 2003 Oct 1;32(5):847–53.
- 471 16. Oloyede IP, Ekrikpo UE, Ekanem EE. Lung Function Indices of Children Exposed to Wood
472 Smoke in a Fishing Port in South-South Nigeria. *J Trop Pediatr*. 2013 Oct 1;59(5):399–402.
- 473 17. Fullerton DG, Suseno A, Semple S, Kalambo F, Malamba R, White S, et al. Wood smoke
474 exposure, poverty and impaired lung function in Malawian adults. *Int J Tuberc Lung Dis*.
475 2011 Mar 1;15(3):391–8.
- 476 18. García-Sancho MC, García-García L, Báez-Saldaña R, Ponce-de-León A, Sifuentes-Osornio
477 J, Bobadilla-del-Valle M, et al. Indoor pollution as an occupational risk factor for
478 tuberculosis among women: a population-based, gender oriented, case-control study in
479 Southern Mexico. :8.
- 480 19. Pérez-Padilla R, Pérez-Guzmán C, Báez-Saldaña R, Torres-Cruz A. Cooking with biomass
481 stoves and tuberculosis: a case control study. *Int J Tuberc Lung Dis Off J Int Union Tuberc
482 Lung Dis*. 2001 May;5(5):441–7.
- 483 20. Wright RJ, Brunst KJ. Programming of respiratory health in childhood: influence of outdoor
484 air pollution. *Curr Opin Pediatr*. 2013 Apr;25(2):232–9.
- 485 21. Hsu HL, Chiu YM, Coull BA, Schwartz J, Lee A, Wright RO, et al. Prenatal Particulate Air
486 Pollution and Asthma Onset in Urban Children. Identifying Sensitive Windows and Sex
487 Differences. *Am J Respir Crit Care Med*. 2015 Nov;192(9):1052–9.
- 488 22. Stapleton A, Casas M, García J, García R, Sunyer J, Guerra S, et al. Associations between
489 pre- and postnatal exposure to air pollution and lung health in children and assessment of
490 CC16 as a potential mediator. *Environ Res*. 2022 Mar 1;204:111900.
- 491 23. Schultz ES, Hallberg J, Bellander T, Bergström A, Bottai M, Chiesa F, et al. Early-Life
492 Exposure to Traffic-related Air Pollution and Lung Function in Adolescence. *Am J Respir
493 Crit Care Med*. 2016 Jan 15;193(2):171–7.
- 494 24. Black C, Gerriets JE, Fontaine JH, Harper RW, Kenyon NJ, Tablin F, et al. Early Life
495 Wildfire Smoke Exposure Is Associated with Immune Dysregulation and Lung Function
496 Decrements in Adolescence. *Am J Respir Cell Mol Biol*. 2017 May 1;56(5):657–66.

- 497 25. Li L, Jick S, Breitenstein S, Hernandez G, Michel A, Vizcaya D. Pulmonary arterial
498 hypertension in the USA: an epidemiological study in a large insured pediatric population.
499 *Pulm Circ.* 2017 Mar;7(1):126–36.
- 500 26. Li Q, Andrade SE, Cooper WO, Davis RL, Dublin S, Hammad TA, et al. Validation of an
501 algorithm to estimate gestational age in electronic health plan databases. *Pharmacoepidemiol*
502 *Drug Saf.* 2013 May;22(5):524–32.
- 503 27. Butler AM, Layton JB, Li D, Hudgens MG, Boggess KA, McGrath LJ, et al. Predictors of
504 Low Uptake of Prenatal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular
505 Pertussis Immunization in Privately Insured Women in the United States. *Obstet Gynecol.*
506 2017 Apr;129(4):629–37.
- 507 28. Truven Health Analytics/IBM Watson Health. IBM Micromedex RedBook [Internet]. 2021.
508 Available from: <https://www.micromedexsolutions.com>
- 509 29. Up To Date. Up To Date. 2021.
- 510 30. Rolph GD, Draxler RR, Stein AF, Taylor A, Ruminski MG, Kondragunta S, et al.
511 Description and Verification of the NOAA Smoke Forecasting System: The 2007 Fire
512 Season. *Weather Forecast.* 2009 Apr 1;24(2):361–78.
- 513 31. Schroeder W, Ruminski M, Csiszar I, Giglio L, Prins E, Schmidt C, et al. Validation
514 analyses of an operational fire monitoring product: The Hazard Mapping System. *Int J*
515 *Remote Sens.* 2008 Oct 20;29(20):6059–66.
- 516 32. OFFICE OF POLICY DEVELOPMENT AND RESEARCH (PD&R). HUD USPS ZIP
517 CODE CROSSWALK FILES [Internet]. U.S. Department of Housing and Urban
518 Development; [cited 2021 Nov 12]. Available from:
519 https://www.huduser.gov/portal/datasets/usps_crosswalk.html#data
- 520 33. Wilson, Ron, Din, Alexander. Understanding and Enhancing the U.S. Department of
521 Housing and Urban Development’s ZIP Code Crosswalk Files. *Cityscape J Policy Dev Res.*
522 2018;20(2):277–94.
- 523 34. Snowden JM, Bovbjerg ML, Dissanayake M, Basso O. The curse of the perinatal
524 epidemiologist: inferring causation amidst selection. *Curr Epidemiol Rep.* 2018
525 Dec;5(4):379–87.
- 526 35. Willson BE, Gee NA, Willits NH, Li L, Zhang Q, Pinkerton KE, et al. Effects of the 2018
527 Camp Fire on birth outcomes in non-human primates: Case-control study. *Reprod Toxicol.*
528 2021 Oct 1;105:128–35.
- 529 36. Bongaerts E, Nawrot TS, Van Pee T, Ameloot M, Bové H. Translocation of (ultra)fine
530 particles and nanoparticles across the placenta; a systematic review on the evidence of in
531 vitro, ex vivo, and in vivo studies. *Part Fibre Toxicol.* 2020 Nov 2;17(1):56.

- 532 37. Bongaerts E, Aengenheister L, Dugershaw BB, Manser P, Roeffaers MBJ, Ameloot M, et al.
533 Label-free detection of uptake, accumulation, and translocation of diesel exhaust particles in
534 ex vivo perfused human placenta. *J Nanobiotechnology*. 2021 May 17;19(1):144.
- 535 38. Engelen L. Translocation of airborne black carbon particles from mother to unborn child: an
536 ENVIRONAGE birth cohort study. :29.
- 537 39. Chang J, Streitman D. Physiologic Adaptations to Pregnancy. *Neurol Clin*. 2012 Aug
538 1;30(3):781–9.
- 539 40. Fleming S, Thompson M, Stevens R, Heneghan C, Plüddemann A, Maconochie I, et al.
540 Normal ranges of heart rate and respiratory rate in children from birth to 18 years: a
541 systematic review of observational studies. *Lancet*. 2011 Mar 19;377(9770):1011–8.
- 542 41. Bai H, Capitanio JP, Miller LA, Clougherty JE. Social status and susceptibility to wildfire
543 smoke among outdoor-housed female rhesus monkeys: A natural experiment. *Heliyon*. 2021
544 Nov 1;7(11):e08333.
- 545 42. Schultz ES, Gruzieva O, Bellander T, Bottai M, Hallberg J, Kull I, et al. Traffic-related Air
546 Pollution and Lung Function in Children at 8 Years of Age: A Birth Cohort Study. *Am J*
547 *Respir Crit Care Med*. 2012 Dec 15;186(12):1286–91.
- 548 43. Jedrychowski WA, Perera FP, Spengler JD, Mroz E, Stigter L, Flak E, et al. Intrauterine
549 exposure to fine particulate matter as a risk factor for increased susceptibility to acute
550 broncho-pulmonary infections in early childhood. *Int J Hyg Environ Health*. 2013
551 Jul;216(4):395–401.
- 552 44. Odo DB, Yang IA, Knibbs LD. A Systematic Review and Appraisal of Epidemiological
553 Studies on Household Fuel Use and Its Health Effects Using Demographic and Health
554 Surveys. *Int J Environ Res Public Health*. 2021 Feb 3;18(4):1411.
- 555 45. Karr C, Demers P, Koehoorn M. Influence of ambient air pollutant sources on clinical
556 encounters for infant bronchiolitis. *Am J Respir Crit Care Med*. 2009;180:995–1001.
- 557 46. Seeni I, Ha S, Nobles C, Liu D, Sherman S, Mendola P. Air pollution exposure during
558 pregnancy: maternal asthma and neonatal respiratory outcomes. *Ann Epidemiol*. 2018 Sep
559 1;28(9):612-618.e4.
- 560 47. Rosa MJ, Just AC, Kloog I, Pantic I, Schnaas L, Lee A, et al. Prenatal particulate matter
561 exposure and wheeze in Mexican children: Effect modification by prenatal psychosocial
562 stress. *Ann Allergy Asthma Immunol*. 2017 Sep 1;119(3):232-237.e1.
- 563 48. Chiu YHM, Coull BA, Sternthal MJ, Kloog I, Schwartz J, Cohen S, et al. Effects of prenatal
564 community violence and ambient air pollution on childhood wheeze in an urban population.
565 *J Allergy Clin Immunol*. 2014 Mar 1;133(3):713-722.e4.
- 566 49. Soh SE, Goh A, Teoh OH, Godfrey KM, Gluckman PD, Shek LPC, et al. Pregnancy
567 Trimester-Specific Exposure to Ambient Air Pollution and Child Respiratory Health

- 568 Outcomes in the First 2 Years of Life: Effect Modification by Maternal Pre-Pregnancy BMI.
569 Int J Environ Res Public Health. 2018 May;15(5):996.
- 570 50. Latzin P, Rössli M, Huss A, Kuehni CE, Frey U. Air pollution during pregnancy and lung
571 function in newborns: a birth cohort study. Eur Respir J. 2009 Mar 1;33(3):594–603.
- 572 51. Jedrychowski WA, Perera FP, Maugeri U, Mroz E, Klimaszewska-Rembiasz M, Flak E, et
573 al. Effect of prenatal exposure to fine particulate matter on ventilatory lung function of
574 preschool children of non-smoking mothers. Paediatr Perinat Epidemiol. 2010;24(5):492–
575 501.
- 576 52. Land SC, Wilson SM. Redox Regulation of Lung Development and Perinatal Lung
577 Epithelial Function. Antioxid Redox Signal. 2005 Jan;7(1–2):92–107.
- 578 53. Kajekar R. Environmental factors and developmental outcomes in the lung. Pharmacol Ther.
579 2007 May 1;114(2):129–45.
- 580 54. Korten I, Ramsey K, Latzin P. Air pollution during pregnancy and lung development in the
581 child. Paediatr Respir Rev. 2017 Jan 1;21:38–46.
- 582 55. Dugershaw BB, Aengenheister L, Hansen SSK, Hougaard KS, Buerki-Thurnherr T. Recent
583 insights on indirect mechanisms in developmental toxicity of nanomaterials. Part Fibre
584 Toxicol. 2020 Jul 11;17(1):31.
- 585 56. Veras MM, de Oliveira Alves N, Fajersztajn L, Saldiva P. Before the first breath: prenatal
586 exposures to air pollution and lung development. Cell Tissue Res. 2017 Mar 1;367(3):445–
587 55.
- 588 57. Brown AP, Cai L, Laufer BI, Miller LA, LaSalle JM, Ji H. Long-term effects of wildfire
589 smoke exposure during early life on the nasal epigenome in rhesus macaques. Environ Int.
590 2022 Jan 1;158:106993.
- 591 58. O’ Lenick CR, Chang HH, Kramer MR, Winkquist A, Mulholland JA, Friberg MD, et al.
592 Ozone and childhood respiratory disease in three US cities: evaluation of effect measure
593 modification by neighborhood socioeconomic status using a Bayesian hierarchical approach.
594 Environ Health. 2017 Apr 5;16(1):36.
- 595 59. Chen L, Bell EM, Caton AR, Druschel CM, Lin S. Residential mobility during pregnancy
596 and the potential for ambient air pollution exposure misclassification. Environ Res. 2010 Feb
597 1;110(2):162–8.
- 598 60. Pennington AF, Strickland MJ, Klein M, Zhai X, Russell AG, Hansen C, et al. Measurement
599 error in mobile source air pollution exposure estimates due to residential mobility during
600 pregnancy. J Expo Sci Environ Epidemiol. 2017 Sep;27(5):513–20.
- 601 61. Carey MA, Card JW, Voltz JW, Arbes SJ, Germolec DR, Korach KS, et al. It’s all about sex:
602 gender, lung development and lung disease. Trends Endocrinol Metab. 2007 Oct
603 1;18(8):308–13.

604 62. Minghetti L, Greco A, Zanardo V, Suppiej A. Early-life sex-dependent vulnerability to
605 oxidative stress: the natural twinning model. *J Matern Fetal Neonatal Med.* 2013
606 Feb;26(3):259–62.

607

Tables

Table 1. Cohort composition in the full cohort and the gestational age sub-cohort, overall and by sex.

	<u>Full cohort</u>			<u>Gestational age sub-cohort</u>		
	ALL CHILDREN (N = 182,387)	MALE CHILDREN (N=93,321)	FEMALE CHILDREN (N = 89,066)	ALL CHILDREN (N = 113,154)	MALE CHILDREN (N=57,682)	FEMALE CHILDREN (N=55,472)
Birth Season						
Spring	50,733 (27.8%)	26,128 (28.0%)	24,605 (27.6%)	32,269 (28.5%)	16,546 (28.7%)	15,723 (28.3%)
Summer	50,290 (27.6%)	25,801 (27.6%)	24,489 (27.5%)	31,858 (28.2%)	16,345 (28.4%)	15,513 (28.0%)
Fall	44,777 (24.6%)	22,708 (24.3%)	22,069 (24.8%)	26,338 (23.3%)	13,294 (23.1%)	13,044 (23.5%)
Winter	36,587 (20.1%)	18,684 (20.0%)	17,903 (20.1%)	22,689 (20.1%)	11,497 (20.0%)	11,192 (20.2%)
Birth Year						
2010	25,031 (13.7%)	12,513 (13.4%)	12,518 (14.1%)	15,391 (13.6%)	7,614 (13.2%)	7,777 (14.0%)
2011	27,143 (14.9%)	13,841 (14.8%)	13,302 (14.9%)	18,203 (16.1%)	9,225 (16.0%)	8,978 (16.2%)
2012	32,721 (17.9%)	16,736 (17.9%)	15,985 (17.9%)	23,127 (20.4%)	11,780 (20.5%)	11,347 (20.5%)
2013	32,438 (17.8%)	16,686 (17.9%)	15,752 (17.7%)	23,343 (20.6%)	11,924 (20.7%)	11,419 (20.6%)
2014	27,543 (15.1%)	14,196 (15.2%)	13,347 (15.0%)	21,279 (18.8%)	11,003 (19.1%)	10,276 (18.5%)
2015	18,933 (10.4%)	9,833 (10.5%)	9,100 (10.2%)	11,811 (10.4%)	6,136 (10.7%)	5,675 (10.2%)
2016	18,578 (10.2%)	9,516 (10.2%)	9,062 (10.2%)	-	-	-
Gestational Age						
less than 28 wks	449 (0.2%)	237 (0.3%)	212 (0.2%)	449 (0.4%)	237 (0.4%)	212 (0.4%)
28 to 36 wks	8,433 (4.6%)	4,396 (4.7%)	4,037 (4.5%)	8,433 (7.5%)	4,396 (7.6%)	4,037 (7.3%)
greater than 36 wks	104,216 (57.1%)	53,049 (56.8%)	51,223 (57.5%)	104,216 (92.1%)	53,049 (92.1%)	51,223 (92.3%)
missing	69,289 (38%)	35,639 (38.2%)	33,594 (37.7%)	-	-	-
Upper respiratory medication claim						
No	179,939 (98.7%)	91,935 (98.5%)	88,004 (98.8%)	111,752 (98.8%)	56,880 (98.8%)	54,872 (98.9%)
Yes	2,448 (1.3%)	1,386 (1.5%)	1,062 (1.2%)	1,402 (1.2%)	802 (1.4%)	600 (1.1%)
Lower respiratory medication claim						
No	148,646 (81.5%)	73,668 (78.9%)	74,978 (84.2%)	92,707 (81.9%)	45,810 (79.6%)	46,897 (84.5%)
Yes	33,741 (18.5%)	19,653 (21.1%)	14,088 (15.8%)	20,447 (18.1%)	11,872 (20.6%)	8,575 (15.5%)
Systemic anti-inflammatory medication claim						
No	158,348 (86.8%)	79,068 (84.7%)	79,280 (89.0%)	98,549 (87.1%)	49,048 (85.2%)	49,501 (89.2%)
Yes	24,039 (13.2%)	14,253 (15.3%)	9,786 (11%)	14,605 (12.9%)	8,634 (15%)	5,971 (10.8%)

Table 2. Mixed effects cox model of smoke exposure during post-partum trimester at the 25% exposure threshold, in all eligible children and stratified by sex. P1 and P2 periods correspond to 0-12 and 13-24 weeks, respectively. Models are adjusted for birth-season, birthyear and, where applicable, sex, with a random intercept for MSA. All exposures are the average weekly number of smoke-days in the given post-partum period. RX = prescribed medication claim.

	Exposure	ALL CHILDREN (N = 182,387)	MALE CHILDREN (N = 93,321)	FEMALE CHILDREN (N = 89,066)
		HR (95% CI)	HR (95% CI)	HR (95% CI)
Upper respiratory RX	P1	1.094 (1.005, 1.191)	1.055 (0.940, 1.185)	1.123 (0.994, 1.270)
	P2	1.108 (1.016, 1.209)	1.128 (1.004, 1.266)	1.072 (0.942, 1.220)
Lower respiratory RX	P1	1.007 (0.983, 1.031)	1.013 (0.982, 1.045)	0.992 (0.955, 1.030)
	P2	0.980 (0.955, 1.007)	0.971 (0.938, 1.005)	0.987 (0.947, 1.029)
Systemic Anti-inflammatory RX	P1	1.001 (0.975, 1.028)	0.995 (0.961, 1.030)	1.008 (0.966, 1.051)
	P2	0.996 (0.969, 1.025)	1.004 (0.968, 1.042)	0.980 (0.938, 1.025)

Table 3. Mixed effects cox model results of smoke exposure during gestational periods at the 25% exposure threshold, in all eligible children and stratified by sex. Models are adjusted for birth season, birthyear and, where applicable, sex, with a random intercept for MSA. The first and second N values correspond to the entire cohort (full cohort) and the cohort portion whose gestational age estimate was available to estimate wildfire smoke-day exposure (GA sub-cohort), respectively. All exposures are the average weekly number of smoke-days in the given period. RX = prescribed medication claim.

Outcome	Cohort	Exposure	ALL CHILDREN	MALE CHILDREN	FEMALE CHILDREN
			(N = 182,387 / 113,154)	(N = 93,321 / 57,682)	(N = 89,066 / 55,472)
			HR (95% CI)	HR (95% CI)	HR (95% CI)
Upper respiratory RX	Full cohort	T1	1.082 (0.985, 1.188)	1.026 (0.902, 1.167)	1.140 (0.997, 1.303)
		T2	0.978 (0.876, 1.093)	1.079 (0.935, 1.245)	0.857 (0.722, 1.018)
		T3	0.913 (0.821, 1.014)	0.884 (0.766, 1.020)	0.948 (0.812, 1.107)
Upper respiratory RX	GA sub-cohort	T1	1.094 (0.974, 1.229)	1.066 (0.910, 1.249)	1.121 (0.949, 1.324)
		T2	0.935 (0.806, 1.085)	0.978 (0.806, 1.186)	0.882 (0.701, 1.108)
		T3	0.948 (0.833, 1.080)	0.957 (0.804, 1.140)	0.931 (0.770, 1.127)
Lower respiratory RX	Full cohort	T1	0.977 (0.951, 1.003)	0.960 (0.927, 0.993)	0.997 (0.956, 1.039)
		T2	0.986 (0.957, 1.017)	0.987 (0.949, 1.027)	0.978 (0.933, 1.026)
		T3	0.992 (0.966, 1.019)	1.004 (0.969, 1.040)	0.970 (0.930, 1.012)
Lower respiratory RX	GA sub-cohort	T1	0.966 (0.935, 0.999)	0.959 (0.918, 1.002)	0.969 (0.920, 1.021)
		T2	0.968 (0.930, 1.008)	0.966 (0.917, 1.018)	0.962 (0.903, 1.025)
		T3	0.972 (0.939, 1.005)	0.982 (0.940, 1.027)	0.948 (0.899, 1.000)
Systemic Anti-inflam. RX	Full cohort	T1	0.976 (0.948, 1.005)	0.978 (0.941, 1.016)	0.973 (0.929, 1.018)
		T2	0.968 (0.935, 1.001)	0.967 (0.925, 1.010)	0.967 (0.916, 1.020)
		T3	0.996 (0.966, 1.027)	1.008 (0.968, 1.049)	0.975 (0.930, 1.022)
Systemic Anti-inflam. RX	GA sub-cohort	T1	0.962 (0.927, 0.997)	0.959 (0.914, 1.006)	0.963 (0.910, 1.019)
		T2	0.946 (0.905, 0.989)	0.921 (0.869, 0.976)	0.982 (0.917, 1.053)
		T3	0.989 (0.953, 1.027)	1.024 (0.975, 1.075)	0.935 (0.882, 0.992)

Figure Captions

Figure 1. Cohort construction. WA, OR, CA, MT, NV, and ID refer to the states of Washington, Oregon, California, Montana, Nevada, and Idaho, respectively. MSA is Metropolitan Statistical Area and CONUS is Continental United States.

Figure 2. Spatial distribution of total number of smoke-days (2010-2016) at each MSA for the (a) 0%, (b) 25%, and (c) 50% thresholds. Thresholds are defined as the population-weighted percentage of zip codes within an MSA required to experience a smoke-day, in order to assign a smoke-day to the MSA.

Figure 3. Hazard ratio and confidence intervals for the relationship of average weekly smoke-days and first use of prescription outcome, in each averaging period at the 25% exposure threshold, for all children (green square), and within strata of male children (purple diamonds) and female children (orange circle). The Cox proportional hazards models were adjusted for birth season, birth year, infant sex and included a random intercept for metropolitan statistical area; infant sex covariate was omitted in infant sex-stratified models. rx = prescribed medication claim; T1-T3 refer to the first-third trimesters; P1 and P2 refer to the first and second 12-week post-natal period.

2,088,936 live births
with estimable
birthdates in CONUS
(2010-16)

1,851,933
in states outside of WA,
OR, CA, MT, NV, & ID

237,003 born into
MSAs in the study
region




52,300 without
prescription coverage

184,703 with
prescription coverage

184,703 with complete
smoke density day
exposure estimates

113,154
with gestational age

71,549 without
gestational age

a**b****c****Total smoke days**


- 70 or fewer
- 71-140
- 141-210
- 211-350
- more than 350

Upper Respiratory


Lower Respiratory

Systemic Anti-Inflammatory

Full Cohort



Gestational Age Cohort



Postnatal (Full Cohort)

